INTRODUCTION
Foetal vibroacoustic stimulation is a simple, non-invasive technique where a device is placed on the maternal abdomen over the region of the foetal head and sound is emitted at a predetermined level for several seconds. It is hypothesized that the resultant startle reflex in the foetus and subsequent foetal heart rate acceleration or transient tachycardia following vibroacoustic stimulation provide reassurance of foetal well-being. This technique has been proposed as a tool to assess foetal well-being in high risk patients. 1 Acceleration of foetal health surveillance (FHS) observed with foetal movements is regarded as a reliable sign of foetal well-being. Often foetus is asleep and there is absence of spontaneous foetal heart rate (FHR) acceleration, manual manipulation, auditory or visual stimuli has been shown to evoke a response of FHR acceleration during intrapartum period. 2, 3 Testing prenatal habituation to vibroacoustic stimulation may play a role in evaluating the performance of the foetal central nervous system and therefore may be predictive of subsequent development after birth. This possibility is supported further is so far as deficits in central nervous system volume and function restrict the response to VAS in the anencephalic foetus. The use of VAS in conjunction with an abnormal biophysical profile or in high risk pregnancies may provide reassurance of foetal well-being. Under the guidance of usg fetal head is located and stimulator is used for 3 secs, response of fetal heart rate and fetal movement noted on the screen. Acceleration of FHR >15 bpm from base line and persistence for 15 seconds is indicative of reactive test, the test is repeated for 3 times at interval of 10 minutes, and if does not show the changes then labeled as non-reactive test. Patients are categorized on this basis as reactive and non-reactive test and further management done accordingly.
RESULTS
The high risk pregnant patients included in this study are oligohydramnios, IUGR, post-dated, diabetes mellitus and gestational hypertension. The age group, demographic profile and education level analysed [ The patients also categorized on the basis of gestational age term and preterm > 37 wks. And < 37 wks. [ Table- 6]. Patients less than 37 weeks received 2 dosage of betnesol for fetal lung maturity. VAST done among all these patients and according to fetal response divided into VAST reactive and non-reactive. In 162 (81%) patients VAST was reactive and 38 (19%) non-reactive. Total babies shifted to NICU 13 (6.5%), 4 babies expired (2%) and 9 (4.5%) improved. Thus VAST has good correlation in prediction of fetal outcome but further studies and trials still needs to establish a definite role in prediction of fetal jeopardy.
DISCUSSION
The idea that the fetus responds to extra uterine sound stimuli came from the observation that a woman felt an increase in fetal movement during the audience applause at a concert (Forbes and Forbes, 1927) . Most of the startle reflex or fetal recoil is felt by the mother. Since palpable or visualized fetal movements after acoustic stimulation is almost always associated with a reactive NST (98%), this is a simple means to assess the neurological status of the unborn child (Michael et al, 1985) . 4 Vibroacoustic stimulation also alters the fetal behavioral state from 1F to 2F or from 2F to 4F state. The time spent in state 1F decreases, while 4F state is significantly more commonly seen after significantly more commonly seen after stimulation (Devoe et al, 1990) . 5 Fetal movement after stimulation has also correlated with a biophysical profile of >8 (Sarinoglu et al,1996) . 6 In our study, 19% of the patients showed non -reactive VAST, rate of caesarean section was 86.84%, meconium aspiration rate 88%, babies admitted to NICU 6.5% and 2% expired. Results were comparable to study done by Kavitha et al 7 24% non-reactive VAST, rate of caesarean 68.8%, meconium aspiration 68.8%, NICU admission rate 12.5% and baby expired 6.3%. Sarno AP et al 8 in their study showed VAST in early period as a predictor of subsequent condition of the fetus in utero. Currently no randomized controlled trials that address the safety and efficacy of VAS used to assess fetal well-being in labour in the presence of a nonreassuring CTG trace. Although VAS has been proposed as a simple, non-invasive tool for assessment of fetal well-being, there is insufficient evidence from randomized trials on which to base recommendations for use of VAS in the evaluation of fetal well-being in labour in the presence of a nonreassuring CTG trace.
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CONCLUSIONS
Vibroacoustic stimulation test is non -invasive, less time consuming, easy non-stress test to know the foetal wellbeing in-utero. But still there is need of randomized control trials to establish its effective role in prediction of foetal outcome.
